New Imaging Test Could Detect Heart Damage in Breast Cancer Patients Receiving Chemotherapy

A new nuclear imaging technique may help identify women at increased risk of heart damage due to their cancer treatment. The new imaging test uses the radiotracer technetium-99 labelled Annexin V, which was developed by Atreus, an Ottawa-based company that was later acquired by Advanced Accelerator Applications, a developer of innovative radiopharmaceuticals. Annexin is an investigational radiotracer and currently has been approved only for investigational use.